Report Overview

According to the deep-dive market assessment study by Growth Plus Reports, the global amyotrophic lateral sclerosis market was valued at US$ 3.0 billion in 2021 and is expected to register a revenue CAGR of 8.5% to reach US$ 6.7 billion by 2030.

Amyotrophic Lateral Sclerosis Market Fundamentals

Amyotrophic lateral sclerosis (ALS), sometimes known as Lou Gehrig's disease, is a progressive neurodegenerative disease that affects nerve cells in the central nervous system that govern voluntary muscles. Muscle twitching, stiffness, and weakness due to a decrease in the size of muscles in the legs or arms are some of the usual symptoms. Around 50% of patients with ALS may lose their ability to swallow, breathe, speak, walk, and use their hands. According to the National Institute of Neurological Disorders and Stroke (NINDS), patients with ALS often die due to respiratory failure within 3-5 years of progressive paralysis. It further indicates that sporadic ALS is the most common, accounting for 90% to 95% of all cases in the United States, while familial ALS accounts for the remainder.

[63356345]

Amyotrophic Lateral Sclerosis Market Dynamics 

With rising obesity rates worldwide, the necessity for a comprehensive examination of this healthcare issue prompted the creation of this report. Key market drivers include increased binge eating and junk food consumption, lack of interest in regular exercise, and rise in stress levels. The report offers greater detail regarding these topics, focusing on the growing need for ALS treatment. Furthermore, an increase in the launch of novel pharmaceuticals, an increase in healthcare expenditure, and a well-established healthcare infrastructure are projected to boost market expansion. The growth in strategic collaborations between major organizations and research institutes for the development of ALS treatment, as well as the increase in government initiatives to examine rare disease research and FDA approvals, are likely to open a slew of new possibilities for revenue growth in the amyotrophic lateral sclerosis treatment market.

Amyotrophic Lateral Sclerosis Market Ecosystem 

The global amyotrophic lateral sclerosis market has been analyzed from four perspectives: drug type, treatment type, end user, and region.

Amyotrophic Lateral Sclerosis Market by Drug Type

[42424211]

Based on the drug type, the global amyotrophic lateral sclerosis market has been segmented into sporadic amyotrophic lateral sclerosis (ALS) and familial amyotrophic lateral sclerosis (ALS).

During the forecast period, the sporadic ALS segment is expected to dominate the global amyotrophic lateral sclerosis market. Sporadic ALS is the most common, accounting for 90% to 95% of all instances in the United States, with the familial type accounting for the remainder. On the contrary, familial ALS is the fastest-growing segment. Familial ALS (FALS) is a hereditary condition in which each baby has a 50% risk of inheriting the genetic mutation and developing the disorder. The deficiency is most typically observed in the C9ORF72 gene in 25%-40% of individuals with familial ALS. A mutation in this gene also causes frontotemporal dementia (FTD), which can develop alongside ALS as a comorbidity known as ALS-FTD.

Amyotrophic Lateral Sclerosis Market by Treatment Type 

Based on the treatment type, the global amyotrophic lateral sclerosis market has been segmented into medication therapy, stem cell therapies, respiratory therapy, speech therapy, and others.

The medication physical therapy segment dominates the market. It includes two FDA-approved medications for treatment, namely, Rlutek (riluzole) and Radicava (edaravone). The stem cell therapies segment is also projected to develop significantly as the desire for new techniques and improved treatment increases.

Amyotrophic Lateral Sclerosis Market by End User

Based on the end user, the global amyotrophic lateral sclerosis market has been segmented into hospitals, specialty centers, research and academic institutes, and others.

The hospitals segment is expected to dominate the market during the forecast period, and this trend is expected to continue during the forecast period. Patients are increasingly favoring hospital pharmacies over other end users. This can be ascribed to simple and quick access to a diverse choice of drugs and sufficient products provided by hospitals.

Amyotrophic Lateral Sclerosis Market by Region 

Based on the region, the global amyotrophic lateral sclerosis market has been segmented into North America, Europe, Asia Pacific, and the Rest of the World.

North America is expected to dominate a significant market share in the global amyotrophic lateral sclerosis (ALS) treatment market due to the increasing incidence of ALS diseases, growing demand for ALS drugs, rising healthcare expenditure, well-established healthcare infrastructure, favorable reimbursement policies, and technological advancements in the region. Furthermore, the presence of the older population exacerbates these issues. The majority of people over the age of 50 are more likely to develop this disorder, according to the Centers for Disease Control and Prevention (CDC) and the Organization for Toxic Substances and Disease Registry (ATSDR). This factor is expected to fuel the demand in the amyotrophic lateral sclerosis market in North America.

Amyotrophic Lateral Sclerosis Market Competitive Landscape 

The prominent market players in the global amyotrophic lateral sclerosis market include:

• Mitsubishi Tanabe Pharma Corporation
• Otsuka Pharmaceutical Co. Ltd. 
• Sun Pharmaceutical Industries Ltd.
• CORESTEM, Inc.
• BrainStorm Cell Limited
• Amylyx Pharmaceuticals Inc.
• AB Science
• Ionis Pharmaceuticals, Inc.
• Ionis Pharmaceuticals
• Biohaven Pharmaceutical
• Biogen Inc.
• F.Hoffmann-La Roche AG.
• Jazz Pharmaceuticals
• Taiwan Biotech Co. Ltd. 
• Novartis AG 

Amyotrophic Lateral Sclerosis Market Strategic Developments 

• In June 2022, Amylyx Pharmaceuticals Inc’s new medicine ALBRIOZA (also known as AMX0035) for ALS was approved in Canada.
• In May 2022, the U.S. Food and Drug Administration (FDA) approved RADICAVA ORS (edaravone) by Mitsubishi Tanabe Pharma America for the treatment of ALS.
• In 2021, Neurimune and TVM Capital Life Science co-founded ALS Pharma AG. They recruited the first patient in a multicenter, placebo-controlled phase II clinical trial testing AP101 in patients with amyotrophic lateral cord syndrome.
• In 2021, Mitsubishi Tanabe Pharmaceuticals completed the third phase of its Edaravone oral suspension, which was expected to be used to treat ALS.

Frequently Asked Questions About This Report